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Overall, the topic areas “Market Launch”, “Price Negotiations” and “Process” were
most controversial. Regarding stakeholder groups, those experts belonging to
Pharmaceutical industry displayed the largest differences to those of the Payor
group. 16 experts answered the open-ended question about “costs of dossier pro-
cess” ranging between €100,000 and €500,000 per drug assessed. CONCLUSIONS:
We performed a structured survey analysis with experts to assess the new German
benefit assessement process based on their one year experience. Several topics and
items of high controversy between the affected stakeholders were identified. How-
ever, due to the limited quantitative outcomes experience with the AMNOG pro-
cess to date future research is needed to increase our knowledge about the legis-
lation.
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OBJECTIVES: The use of generic medicines, which can generate large savings to
health care budgets, should be supported by incentives on both the supply side and
the demand side. Pharmacists’ remuneration can influence the choice of the dis-
pensed drug. The aim of this study is to provide an overview of different pharma-
cist remuneration systems for generic medicines in Europe, with a view to explor-
ing how pharmacist remuneration systems can contribute to generic medicine
dispensing. METHODS: Data were obtained from a literature review, a Master the-
sis in Pharmaceutical Care at the University of Leuven and a mailing sent to all
members of the Pharmaceutical Group of the European Union with a request for
information about the local remuneration systems of community pharmacists and
the possible existence of reports on discounting practices. RESULTS: Pharmacists’
remuneration in most European countries consists of the combination of a fixed fee
per item and a certain percentage of the acquisition cost or the delivery price of the
medicines. This percentage component can be fixed, regressive or capped for very
high-cost medicines and acts as a disincentive for dispensing generic medicine.
Information on discounting for generic medicines, which is common practice in
several European countries, tends to be confidential. Data showed that discounts
varied from 10% to 70% of the wholesale selling price. CONCLUSIONS: Pharmacists
should not be financially penalized for dispensing generic medicines. Therefore,
their remuneration should move towards a fee-for-performance remuneration in-
stead of a price-dependent reimbursement which is currently used in many Euro-
pean countries. Such a fee-for-performance remuneration system provides a stim-
ulus for generic medicines dispensing as pharmacists are not penalized for
dispensing generic medicines. More and more European countries are moving to-
wards such a remuneration system. Pharmacists’ remuneration systems also need
to account for the loss of income to pharmacists from prohibiting discounting
practices.
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OBJECTIVES: After the Pharmaceutical Market Restructuring Act (AMNOG) took
effect in 2010, almost all pharmaceutical companies consider how to position
themselves differently in health care related value chains. The law offers new
options for the pharmaceutical and medical devices industry to reorganize their
business models in order to become an active and equal partner in integrated care
contracts with insurance companies. This paper examines key success factors for
collaborating with other stakeholders. METHODS: Due to the distinctiveness and
topicality of integrated care contracts, four cases of selective contracting between
the industry and insurance companies were scrutinized. On this basis, experts of
all parties (pharmaceutical industry, health care providers, insurance companies,
and management companies) were interviewed. RESULTS: Whereas insurance
companies and health care providers, as well as health care providers and the
pharmaceutical industry have gained experience in cooperating with each other
(e.g., in clinical trials), fears of contacts between insurance companies and the
pharmaceutical industry still exist. They need to be abolished by establishing ca-
pable structures and a bi-lateral willingness to cooperate. Pivotal elements of se-
lective contracting can be allocated to four segments, namely markets (exceed
certain thresholds such as number of patients enrolled), products (targeting of
“real” care-gaps and physicians’ relief), management (distribution of tasks, evalu-
ation concepts), and financial mechanisms (gain-sharing as means to achieve rev-
enue and profitability). First experiences in Germany have proofed technology-
based contracts to be suitable for inexperienced companies to start with. The level
of complexity of selective contracts and the timely component are often
underestimated. CONCLUSIONS: Pilot projects are now being implemented into
practice which underpins their topicality and the importance of adequate evalua-
tion. Their success depends on the inclusion of relevant partners and the intelli-
gent combination of the stakeholders’ various strengths. The objective is to de-
velop concepts which are applicable outside of Germany on international markets.
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OBJECTIVES: In early 2012, there were a number of serious events in the implant
area. A recent example are the defective breast implants of the French company
Poly Implant Prothese. The second incident concerns ‘metal on metal’ (MoM) hip
implants. These events raised public awareness and started a scientific discussion
in academia and politics on safety issues and monitoring medical devices. Appar-
ently, there is a big lack in the surveillance of medical devices. Therefore, the
objective of this work is to detect existing implant registries in the European Union.
METHODS: A systematic review of the literature was carried out to identify differ-
ent types of implant registries in the European Union Member States (EU MS). The
systematic search for implant registries was performed in the databases PubMed,
Medline, CRD York. All results up to April 2012 were considered. RESULTS: Ninety-
nine registries in the EU MS for different types of implants were identified. As
demonstrated, most registries exist in the field of cardiac implants and arthro-
plasty (34 and 30 within Europe). The distribution of implant registries showed
variation in the different EU MS. For a lot of implant categories, none or very few
registries could be identified. Some countries run more registries than others (UK
15, Portugal 1). CONCLUSIONS: The results show that there is only a limited num-
ber of reviews on registries and a centralized monitoring system in the EU MS is
missing. Our results reveal a lack of transparency concerning number, aim, struc-
ture and quality of registries. This is crucial, as registries work as an early warning
systems for identifying and notifying patients at risk. [The research is supported by
the German Federal Ministry of Education and Research (BMBF), project grant No.
01EX1013B as part of the Centre of Excellence for Medical Technology].
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OBJECTIVES: Transparency Directive (TD) (89/105/EEC) aims to foster the transpar-
ency of measures regulating the pricing and reimbursement decisions of pharma-
ceuticals in European Union Member States. TD establishes a number of funda-
mental principles including strict timelines for the pricing and reimbursement
(P&R) process. Our study focuses on the implementation of the Transparency Di-
rective in Hungary with special focus on time-limits for P&R decisions. METHODS:
We analyzed official decisions in 103 P&R submissions (positive cases with deci-
sions only) made by the National Health Insurance Fund Administration (NHIFA)
between 2004 and 2010. Most of the cases belonged to pharmaceuticals with new
active ingredients and without reimbursement at the time of submission. We ex-
cluded generic drugs and cases without P&R decision from the analysis. In order to
determine the market access time we calculated the time period between the
registration date of the drug by the European Medicines Agency (EMA) or by the
National Institute of Pharmacy (NIP) and the P&R decision. RESULTS: The average
time period from registration to P&R decision was 721 days (min: 46 days, max: 2696
days); from registration to P&R submission was 481 days (min: 1 days, max: 2581
days), from P&R submission to P&R decision was 214 days (min: 7 days, max: 990
days). Hungarian patients get access later to those medicines with centralized EMA
registration compared with medicines with national registration procedure by NIP
(average elapsed time from registration to positive decision was 827 days by EMA,
513 days by NIP). CONCLUSIONS: Periods needed for decisions are generally in
accordance with the 9090 days recommendation of the TD. There is a positive
change in pricing and reimbursement process in Hungary; decision procedure was
shorter in 2010 than it was in 2004. Hungarian patients get new, better medicines
later if the registration was done by EMA.
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OBJECTIVES:Drug development productivity has decreased over the past 10 years.
The objectives are to a) better describe the reasons for discontinuations and b) help
define the scale of the issue around discontinuing products and additional indica-
tions for reasons related to an anticipated lack of pricing and reimbursement
flexibility. METHODS: A restricted and confidential survey to four pharmaceutical
companies on their discontinued projects for lead and follow-on indications during
the period 2005-2009. Reasons for discontinuation distinguished two major cate-
gories, ‘technical’ (including failure to meet safety or efficacy targets) and ‘com-
mercial’ reasons. RESULTS: The four companies reported a total of 1,053 projects
which had been active during the period 2005-2009. Of those, 51% were discontin-
ued (n541) by the end of 2009; 332 were lead indications and 209 were follow-on
indications. About 72% of discontinuations for lead indications were for technical
reasons. The pattern for follow-on indications is more complex. Technical reasons
triggered a smaller proportion of discontinuations, presumably because many
were addressed with the lead indication. However, a greater percentage of the
discontinuations were after Phases II and III, implying higher costs to this point.
Portfolio prioritisations and exiting the disease area accounted for 20% of discon-
tinued projects. CONCLUSIONS: The results for lead indications reinforce previous
results about the growing importance of non-technical i.e. commercial reasons as
drivers for project discontinuations, around 20-25% in our sample. However, our
results show for the first time an analysis for follow-on indications and where no
comparison to previous literature is possible.
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